References
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424. doi: 10.3322/caac.21492
- de Brito BB, da Silva FAF, Soares AS, Pereira VA, Santos MLC, Sampaio MM, et al. Pathogenesis and clinical management of Helicobacter pylori gastric infection. World J Gastroenterol 2019; 25: 5578–89. doi: 10.3748/wjg.v25.i37.5578
- Correa P. Human gastric carcinogenesis: a multistep and multifactorial process − First American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res 1992; 52: 6735–40. PMID: 1458460
- Kapadia CR. Gastric atrophy, metaplasia, and dysplasia: a clinical perspective. J Clin Gastroenterol 2003; 36: S29–36; discussion S61–62. doi: 10.1097/00004836-200305001-00006
- Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol 1999; 94: 2373–9. doi: 10.1111/j.1572-0241.1999.01360.x
- Rokkas T, Rokka A, Portincasa P. A systematic review and meta-analysis of the role of Helicobacter pylori eradication in preventing gastric cancer. Ann Gastroenterol 2017; 30: 414–23. doi: 10.20524/aog.2017.0144
- Wong BC-Y, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al. China Gastric Cancer Study Group. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004; 291: 187–94. doi: 10.1001/jama.291.2.187
- Chen H-N, Wang Z, Li X, Zhou Z-G. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer 2016; 19: 166–75. doi: 10.1007/s10120-015-0462-7
- Hwang Y-J, Kim N, Lee HS, Lee JB, Choi YJ, Yoon H, et al. Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication − a prospective study for up to 10 years. Aliment Pharmacol Ther 2018; 47: 380–90. doi: 10.1111/apt.14424
- Kodama M, Murakami K, Okimoto T, Sato R, Uchida M, Abe T, et al. Ten-year prospective follow-up of histological changes at five points on the gastric mucosa as recommended by the updated Sydney system after Helicobacter pylori eradication. J Gastroenterol 2012; 47: 394–403. doi: 10.1007/s00535-011-0504-9
- Mišak Z, Hojsak I, Homan M. Review: Helicobacter pylori in pediatrics. Helicobacter 2019; 24 (Suppl 1): e12639. doi: 10.1111/hel.12639
- Goh K-L, Chan W-K, Shiota S, Yamaoka Y. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 2011; 16 (Suppl 1): 1–9. doi: 10.1111/j.1523-5378.2011.00874.x
- Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325: 1127–31. doi: 10.1056/NEJM199110173251603
- Hansson LR, Engstrand L, Nyrén O, Lindgren A. Prevalence of Helicobacter pylori infection in subtypes of gastric cancer. Gastroenterology 1995; 109: 885–8. doi: 10.1016/0016-5085(95)90398-4
- Ansari S, Gantuya B, Tuan VP, Yamaoka Y. Diffuse gastric cancer: a summary of analogous contributing factors for its molecular pathogenicity. Int J Mol Sci 2018; 19: 2424. doi: 10.3390/ijms19082424
- Correa P, Haenszel W, Cuello C, Zavala D, Fontham E, Zarama G, et al. Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res 1990; 50: 4737–40.
- Park YH, Kim N. Review of atrophic gastritis and intestinal metaplasia as a premalignant lesion of gastric cancer. J Cancer Prev 2015; 20: 25–40. doi: 10.15430/JCP.2015.20.1.25
- Pimentel-Nunes P, Libânio D, Marcos-Pinto R, Areia M, Leja M, Esposito G, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy 2019; 51: 365–88. doi: 10.1055/a-0859-1883
- Šterbenc A, Jarc E, Poljak M, Homan M. Helicobacter pylori virulence genes. World J Gastroenterol 2019; 25: 4870–884. doi: 10.3748/wjg.v25.i33.4870
- Höcker M, Hohenberger P. Helicobacter pylori virulence factors − one part of a big picture. Lancet 2003; 362: 1231–3. doi: 10.1016/S0140-6736(03)14547-3
- Šterbenc A, Lunar MM, Homan M, Luzar B, Zidar N, Poljak M. Prevalence of the Helicobacter pylori babA2 gene in children mainly depends on the PCR primer set used. Can J Infect Dis Med Microbiol 2020; 2020: 4080248. doi: 10.1155/2020/4080248
- Mobley HL, Island MD, Hausinger RP. Molecular biology of microbial ureases. Microbiol Rev 1995; 59: 451–80. doi: 10.1128/mr.59.3.451-480.1995
- Schwartz JT, Allen L-AH. Role of urease in megasome formation and Helicobacter pylori survival in macrophages. J Leukoc Biol 2006; 79: 1214–25. doi: 10.1189/jlb.0106030
- Eaton KA, Suerbaum S, Josenhans C, Krakowka S. Colonization of gnotobiotic piglets by Helicobacter pylori deficient in two flagellin genes. Infect Immun 1996; 64: 2445–8. doi: 10.1128/iai.64.7.2445-2448.1996
- Kim JS, Chang JH, Chung SI, Yum JS. Molecular cloning and characterization of the Helicobacter pylori fliD gene, an essential factor in flagellar structure and motility. J Bacteriol 1999; 181: 6969–76. doi: 10.1128/JB.181.22.6969-6976.1999
- Howitt MR, Lee JY, Lertsethtakarn P, Vogelmann R, Joubert L-M, Ottemann KM, et al. ChePep controls Helicobacter pylori infection of the gastric glands and chemotaxis in the Epsilonproteobacteria. mBio 2011; 2: e00098–11. doi: 10.1128/mBio.00098-11
- Kao CY, Sheu BS, Sheu SM, Yang HB, Chang WL, Cheng HC, et al. Higher motility enhances bacterial density and inflammatory response in dyspeptic patients infected with Helicobacter pylori. Helicobacter 2012; 17: 411–6. doi: 10.1111/j.1523-5378.2012.00974.x
- Lertsethtakarn P, Ottemann KM, Hendrixson DR. Motility and chemotaxis in Campylobacter and Helicobacter. Annu Rev Microbiol 2011; 65: 389–410. doi: 10.1146/annurev-micro-090110-102908
- Tian W, Jia Y, Yuan K, Huang L, Nadolny C, Dong X, et al. Serum antibody against Helicobacter pylori FlaA and risk of gastric cancer. Helicobacter 2014; 19: 9–16. doi: 10.1111/hel.12095
- Toyoshima O, Nishizawa T, Sakitani K, Yamakawa T, Takahashi Y, Yamamichi N, et al. Serum anti-Helicobacter pylori antibody titer and its association with gastric nodularity, atrophy, and age: a cross-sectional study. World J Gastroenterol 2018; 24: 4061–8. doi: 10.3748/wjg.v24.i35.4061
- Yamaoka Y. Roles of Helicobacter pylori BabA in gastroduodenal pathogenesis. World J Gastroenterol 2008; 14: 4265–72. doi: 10.3748/wjg.14.4265
- Backert S, Clyne M, Tegtmeyer N. Molecular mechanisms of gastric epithelial cell adhesion and injection of CagA by Helicobacter pylori. Cell Commun Signal 2011; 9: 28. doi: 10.1186/1478-811X-9-28
- Ilver D, Arnqvist A, Ogren J, Frick IM, Kersulyte D, Incecik ET, et al. Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science 1998; 279: 373–7. doi: 10.1126/science.279.5349.373
- Gerhard M, Lehn N, Neumayer N, Borén T, Rad R, Schepp W, et al. Clinical relevance of the Helicobacter pylori gene for blood-group antigen-binding adhesin. PNAS 1999; 96: 12778–83. doi: 10.1073/pnas.96.22.12778
- Oleastro M, Gerhard M, Lopes AI, Ramalho P, Cabral J, Sousa Guerreiro A, et al. Helicobacter pylori virulence genotypes in Portuguese children and adults with gastroduodenal pathology. Eur J Clin Microbiol Infect Dis 2003; 22: 85–91. doi: 10.1007/s10096-002-0865-3
- Olfat FO, Zheng Q, Oleastro M, Voland P, Borén T, Karttunen R, et al. Correlation of the Helicobacter pylori adherence factor BabA with duodenal ulcer disease in four European countries. FEMS Immunol Med Microbiol 2005; 44: 151–6. doi: 10.1016/j.femsim.2004.10.010
- Oliveira AG, Santos A, Guerra JB, Rocha GA, Rocha AMC, Oliveira CA, et al. babA2- and cagA-positive Helicobacter pylori strains are associated with duodenal ulcer and gastric carcinoma in Brazil. J Clin Microbiol 2003; 41: 3964–6. doi: 10.1128/jcm.41.8.3964-3966.2003
- Abadi ATB, Rafiei A, Ajami A, Hosseini V, Taghvaei T, Jones KR, et al. Helicobacter pylori homB, but not cagA, is associated with gastric cancer in Iran. J Clin Microbiol 2011; 49: 3191–7. doi: 10.1128/JCM.00947-11
- Šterbenc A, Poljak M, Zidar N, Luzar B, Homan M. Prevalence of the Helicobacter pylori homA and homB genes and their correlation with histological parameters in children. Microb Pathog 2018; 125: 26–32. doi: 10.1016/j.micpath.2018.09.005
- Higashi H, Tsutsumi R, Fujita A, Yamazaki S, Asaka M, Azuma T, et al. Biological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine phosphorylation sites. Proc Natl Acad Sci U S A 2002; 99: 14428–33. doi: 10.1073/pnas.222375399
- Yamazaki S, Yamakawa A, Ito Y, Ohtani M, Higashi H, Hatakeyama M, et al. The CagA protein of Helicobacter pylori is translocated into epithelial cells and binds to SHP-2 in human gastric mucosa. J Infect Dis 2003; 187: 334–7. doi: 10.1086/367807
- Kikuchi K, Murata-Kamiya N, Kondo S, Hatakeyama M. Helicobacter pylori stimulates epithelial cell migration via CagA-mediated perturbation of host cell signaling. Microbes Infect 2012; 14: 470–6. doi: 10.1016/j.micinf.2011.12.003
- Boonyanugomol W, Chomvarin C, Hahnvajanawong C, Sripa B, Kaparakis-Liaskos M, Ferrero RL. Helicobacter pylori cag pathogenicity island (cag-PAI) Involved in bacterial internalization and IL-8 induced responses via NOD1- and MyD88-dependent mechanisms in human biliary epithelial cells. PLoS One 2013; 8: e77358. doi: 10.1371/journal.pone.0077358
- Bentires-Alj M, Paez JG, David FS, Keilhack H, Halmos B, Naoki K, et al. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res 2004; 64: 8816–20. doi: 10.1158/0008-5472.CAN-04-1923
- Hatakeyama M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer 2004; 4: 688–94. doi: 10.1038/nrc1433
- Censini S, Lange C, Xiang Z, Crabtree JE, Ghiara P, Borodovsky M, et al. cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci U S A 1996; 93: 14648–53. doi: 10.1073/pnas.93.25.14648
- Homan M, Luzar B, Kocjan BJ, Orel R, Mocilnik T, Shrestha M, et al. Prevalence and clinical relevance of cagA, vacA, and iceA genotypes of Helicobacter pylori isolated from Slovenian children. J Pediatr Gastroenterol Nutr 2009; 49: 289–96. doi: 10.1097/MPG.0b013e31818f09f2
- Chiurillo MA, Moran Y, Cañas M, Valderrama E, Granda N, Sayegh M, et al. Genotyping of Helicobacter pylori virulence-associated genes shows high diversity of strains infecting patients in western Venezuela. Int J Infect Dis 2013; 17: e750–6.doi: 10.1016/j.ijid.2013.03.004
- Homan M, Hojsak I, Kolaček S. Helicobacter pylori in pediatrics. Helicobacter 2012; 17 (Suppl 1): 43–8. doi: 10.1111/j.1523-5378.2012.00982.x
- Yamaoka Y, Kodama T, Gutierrez O, Kim JG, Kashima K, Graham DY. Relationship between Helicobacter pylori iceA, cagA, and vacA status and clinical outcome: studies in four different countries. J Clin Microbiol 1999; 37: 2274–9. doi: 10.1128/JCM.37.7.2274-2279.1999
- Argent RH, Kidd M, Owen RJ, Thomas RJ, Limb MC, Atherton JC. Determinants and consequences of different levels of CagA phosphorylation for clinical isolates of Helicobacter pylori. Gastroenterology 2004; 127: 514–23. doi: 10.1053/j.gastro.2004.06.006
- Palframan SL, Kwok T, Gabriel K. Vacuolating cytotoxin A (VacA), a key toxin for Helicobacter pylori pathogenesis. Front Cell Infect Microbiol 2012; 2: 92. doi: 10.3389/fcimb.2012.00092
- Hisatsune J, Nakayama M, Isomoto H, Kurazono H, Mukaida N, Mukhopadhyay AK, et al. Molecular characterization of Helicobacter pylori VacA induction of IL-8 in U937 cells reveals a prominent role for p38MAPK in activating transcription factor-2, cAMP response element binding protein, and NF-kappaB activation. J Immunol 2008; 180: 5017–27. doi: 10.4049/jimmunol.180.7.5017
- Atherton JC, Cao P, Peek RM, Tummuru MK, Blaser MJ, Cover TL. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration. J Biol Chem 1995; 270: 17771–7. doi: 10.1074/jbc.270.30.17771
- Abdi E, Latifi-Navid S, Latifi-Navid H, Safarnejad B. Helicobacter pylori vacuolating cytotoxin genotypes and preneoplastic lesions or gastric cancer risk: a meta-analysis. J Gastroenterol Hepatol 2016; 31: 734–44. doi: 10.1111/jgh.13256
- Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161–81. doi: 10.1097/00000478-199610000-00001
- Mutoh H, Sakurai S, Satoh K, Osawa H, Tomiyama T, Kita H et al. Pericryptal fibroblast sheath in intestinal metaplasia and gastric carcinoma. Gut 2005; 54: 33–9. doi: 10.1136/gut.2004.042770
- Reis CA, David L, Correa P, Carneiro F, de Bolós C, Garcia E, et al. Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression. Cancer Res 1999; 59: 1003–7. PMID: 10070955
- Capelle LG, de Vries AC, Haringsma J, Ter Borg F, de Vries RA, Bruno MJ, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 2010; 71: 1150–8. doi: 10.1016/j.gie.2009.12.029
- Lim JH, Kim N, Lee HS, Choe G, Jo SY, Chon I, et al. Correlation between endoscopic and histological diagnoses of gastric intestinal metaplasia. Gut Liver 2013; 7: 41–50. doi: 10.5009/gnl.2013.7.1.41
- Marques-Silva L, Areia M, Elvas L, Dinis-Ribeiro M. Prevalence of gastric precancerous conditions: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2014; 26: 378–87. doi: 10.1097/MEG.0000000000000065
- Song H, Ekheden IG, Zheng Z, Ericsson J, Nyrén O, Ye W. Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. BMJ 2015; 351: h3867. doi: 10.1136/bmj.h3867
- Huang RJ, Choi AY, Truong CD, Yeh MM, Hwang JH. Diagnosis and management of gastric intestinal metaplasia: current status and future directions. Gut Liver 2019; 13: 596–603. doi: 10.5009/gnl19181
- González CA, Sanz-Anquela JM, Gisbert JP, Correa P. Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence. Int J Cancer 2013; 133: 1023–32. doi: 10.1002/ijc.28003
- Gupta S, Tao L, Murphy JD, Camargo MC, Oren E, Valasek MA, et al. Race/ethnicity-, socioeconomic status-, and anatomic subsite-specific risks for gastric cancer. Gastroenterology 2019; 156: 59–62.e4. doi: 10.1053/j.gastro.2018.09.045
- Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am 2002; 11: 235–56. doi: 10.1016/s1055-3207(02)00002-9
- Derakhshan MH, Liptrot S, Paul J, Brown IL, Morrison D, McColl KEL. Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females. Gut 2009; 58: 16–23. doi: 10.1136/gut.2008.161331
- Edgren G, Hjalgrim H, Rostgaard K, Norda R, Wikman A, Melbye M, et al. Risk of gastric cancer and peptic ulcers in relation to ABO blood type: a cohort study. Am J Epidemiol 2010; 172: 1280–5. doi: 10.1093/aje/kwq299
- Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M et al. SEER cancer statistics review, 1975–2016, National Cancer Institute. Bethesda, MD. Available at:
https://seer.cancer.gov/csr/1975_2016/ , based on November 2018 SEER data submission, posted to the SEER web site, April 2019. Updated April 9, 2020. (cited 2021 Feb 22). - Trédaniel J, Boffetta P, Buiatti E, Saracci R, Hirsch A. Tobacco smoking and gastric cancer: review and meta-analysis. Int J Cancer 1997; 72: 565–73. doi: 10.1002/(sici)1097-0215(19970807)72:4<;565::aid-ijc3>3.0.co;2-o
- Kneller RW, You WC, Chang YS, Liu WD, Zhang L, Zhao L, et al. Cigarette smoking and other risk factors for progression of precancerous stomach lesions. J Natl Cancer Inst 1992; 84: 1261–6. doi: 10.1093/jnci/84.16.1261
- Tatsugami M, Ito M, Tanaka S, Yoshihara M, Matsui H, Haruma K, et al. Bile acid promotes intestinal metaplasia and gastric carcinogenesis. Cancer Epidemiol Biomarkers Prev 2012; 21: 2101–7. doi: 10.1158/1055-9965.EPI-12-0730
- Li T, Guo H, Li H, Jiang Y, Zhuang K, Lei C, et al. MicroRNA-92a-1–5p increases CDX2 by targeting FOXD1 in bile acids-induced gastric intestinal metaplasia. Gut 2019; 68: 1751–63. doi: 10.1136/gutjnl-2017-315318
- Bernstein H, Bernstein C, Payne CM, Dvorakova K, Garewal H. Bile acids as carcinogens in human gastrointestinal cancers. Mutat Res 2005; 589: 47–65. doi: 10.1016/j.mrrev.2004.08.001
- Lee S-A, Kang D, Shim KN, Choe JW, Hong WS, Choi H. Effect of diet and Helicobacter pylori infection to the risk of early gastric cancer. J Epidemiol 2003; 13: 162–8. doi: 10.2188/jea.13.162
- Loh JT, Torres VJ, Cover TL. Regulation of Helicobacter pylori cagA expression in response to salt. Cancer Res 2007; 67: 4709–15. doi: 10.1158/0008-5472.CAN-06-4746
- Takahashi M, Nishikawa A, Furukawa F, Enami T, Hasegawa T, Hayashi Y. Dose-dependent promoting effects of sodium chloride (NaCl) on rat glandular stomach carcinogenesis initiated with N-methyl-N′-nitro-N-nitrosoguanidine. Carcinogenesis 1994; 15: 1429–32. doi: 10.1093/carcin/15.7.1429
- Cross AJ, Pollock JRA, Bingham SA. Haem, not protein or inorganic iron, is responsible for endogenous intestinal N-nitrosation arising from red meat. Cancer Res 2003; 63: 2358–60.
- Wiseman M. The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Proc Nutr Soc 2008; 67: 253–6. doi: 10.1017/S002966510800712X
- Ta G, Yi K, Mc S, Mv G, W S, S M, et al. Folic acid increases global DNA methylation and reduces inflammation to prevent Helicobacter-associated gastric cancer in mice. Gastroenterology 2012; 142: 824–33.e7. doi: 10.1053/j.gastro.2011.12.058
- Yanaoka K, Oka M, Ohata H, Yoshimura N, Deguchi H, Mukoubayashi C et al. Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels. Int J Cancer 2009; 125: 2697–703. doi: 10.1002/ijc.24591
- Sung JJ, Lin SR, Ching JY, Zhou LY, To KF, Wang RT, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 2000; 119: 7–14. doi: 10.1053/gast.2000.8550
- Kiriyama Y, Tahara T, Shibata T, Okubo M, Nakagawa M, Okabe A, et al. Gastric-and-intestinal mixed intestinal metaplasia is irreversible point with eradication of Helicobacter pylori. Open Journal of Pathology 2016; 6: 93–104. doi: 10.4236/ojpathology.2016.62012
- Satoh K, Kimura K, Takimoto T, Kihira K. A follow-up study of atrophic gastritis and intestinal metaplasia after eradication of Helicobacter pylori. Helicobacter 1998; 3: 236–40. PMID: 9844064
- Kodama M, Okimoto T, Ogawa R, Mizukami K, Murakami K. Endoscopic atrophic classification before and after H. pylori eradication is closely associated with histological atrophy and intestinal metaplasia. Endosc Int Open 2015; 3: E311–7. doi: 10.1055/s-0034-1392090
- Lu B, Chen M-T, Fan Y-H, Liu Y, Meng L-N. Effects of Helicobacter pylori eradication on atrophic gastritis and intestinal metaplasia: a 3-year follow-up study. World J Gastroenterol 2005; 11: 6518–20. doi: 10.3748/wjg.v11.i41.6518
- Zhou L, Sung JJY, Lin S, Jin Z, Ding S, Huang X, et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chin Med J (Engl) 2003; 116: 11–4. PMID: 12667379
- Lee Y-C, Chiang T-H, Chou C-K, Tu Y-K, Liao W-C, Wu M-S, et al. Association between helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology 2016; 150: 1113–24.e5. doi: 10.1053/j.gastro.2016.01.028
- Akbari M, Tabrizi R, Kardeh S, Lankarani KB. Gastric cancer in patients with gastric atrophy and intestinal metaplasia: a systematic review and meta-analysis. PLoS One 2019; 14: e0219865. doi: 10.1371/journal.pone.0219865
- Huang KK, Ramnarayanan K, Zhu F, Srivastava S, Xu C, Tan ALK, et al. Genomic and Epigenomic profiling of high-risk intestinal metaplasia reveals molecular determinants of progression to gastric cancer. Cancer Cell 2018; 33: 137–50.e5. doi: 10.1016/j.ccell.2017.11.018
- Crider KS, Yang TP, Berry RJ, Bailey LB. Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate’s role. Adv Nutr 2012; 3: 21–38. doi: 10.3945/an.111.000992
- Zhu S, Mason J, Shi Y, Hu Y, Li R, Wahg M, et al. The effect of folic acid on the development of stomach and other gastrointestinal cancers. Chin Med J (Engl) 2003; 116: 15–9. PMID: 12667380
- Lei J, Ren F, Li W, Guo X, Liu Q, Gao H, et al. Use of folic acid supplementation to halt and even reverse the progression of gastric precancerous conditions: a meta-analysis. BMC Gastroenterol 2022; 22: 370. doi: 10.1186/s12876-022-02390-y
- Tan M, Jamali T, Nguyen TH, Galvan A, Sealock RJ, Khan A, et al. Race/ethnicity and birthplace as risk factors for gastric intestinal metaplasia in a multiethnic united states population. Am J Gastroenterol 2022; 117: 280–7. doi: 10.14309/ajg.0000000000001576
- Akpoigbe K, Culpepper-Morgan J, Nwankwo O, Genao A. Predicting gastric intestinal metaplasia in a high-risk population. Cureus 2022; 14: e31502. doi: 10.7759/cureus.31502
- Aumpan N, Vilaichone Rk, Pornthisarn B, Chonprasertsuk S, Siramolpiwat S, et al. Predictors for regression and progression of intestinal metaplasia (IM): a large population-based study from low prevalence area of gastric cancer (IM-predictor trial). PLoS One 2021 16: e0255601. doi: 10.1371/journal.pone.0255601
- Tan MC, Mallepally N, Liu Y, El-Serag HB, Thrift AP. Demographic and lifestyle risk factors for gastric intestinal metaplasia among US veterans. Am J Gastroenterol 2020; 115: 381–7. doi: 10.14309/ajg.0000000000000498
- Aumpan N, Vilaichone RK, Nunanan P, Chonprasertsuk S, Siramolpiwat S, et al. Predictors for development of complete and incomplete intestinal metaplasia (IM) associated with H. pylori infection: a large-scale study from low prevalence area of gastric cancer (IM-HP trial). PLoS One 2020; 15: e0239434. doi: 10.1371/journal.pone.0239434
- Leung WK, Ng EK, Chan WY, Auyeung AC, Chan KF, Lam CC, et al. Risk factors associated with the development of intestinal metaplasia in first-degree relatives of gastric cancer patients. Cancer Epidemiol Biomarkers Prev 2005; 14: 2982–86. doi: 10.1158/1055-9965.EPI-05-0181
- Joo YE, Park HK, Myung DS, Baik GH, Shin JE, Seo GS, et al. Prevalence and risk factors of atrophic gastritis and intestinal metaplasia: a nationwide multicenter prospective study in Korea. Gut Liver 2013; 7: 303–10. doi: 10.5009/gnl.2013.7.3.303
- Tatsuta M, Iishi H, Nakaizumi A, Okuda S, Taniguchi H, Hiyama T, et al. Fundal atrophic gastritis as a risk factor for gastric cancer. Int J Cancer 1993; 53: 70–4. doi: 10.1002/ijc.2910530114
- Nguyen TH, Tan MC, Liu Y, Rugge M, Thrift AP, El-Serag HB. Prevalence of gastric intestinal metaplasia in a multiethnic US veterans’ population. Clin Gastroenterol Hepatol 2021; 19: 269–76. doi: 10.1016/j.cgh.2020.03.015
- Nieuwenburg SAV, Mommersteeg MC, Eikenboom EL, Yu B, den Hollander WJ, Holster IL, et al. Factors associated with the progression of gastric intestinal metaplasia: a multicenter, prospective cohort study. Endosc Int Open 2021; 9: 297–305. doi: 10.1055/a-1314-6626
- Reddy KM, Chang JI, Shi JM, Wu BU. Risk of gastric cancer among patients with intestinal metaplasia of the stomach in a US integrated health care system. Clin Gastroenterol Hepatol 2016; 14: 1420–5. doi: 10.1016/j.cgh.2016.05.045
- Holmes HM, Jove AG, Tan MC, El-Serag HB, Thrift AP. Alcohol consumption and the risk of gastric intestinal metaplasia in a U.S. Veterans population PLoS One 2021; 16: e0260019. doi: 10.1371/journal.pone.0260019. PMID: 34780551
- Kim K, Chang Y, Ahn J, Yang HJ, Ryu S. Low levels of alcohol consumption and risk of intestinal metaplasia: a cohort study. Cancer Epidemiol Biomarkers Prev 2020; 29: 2633–41. doi: 10.1158/1055-9965.EPI-20-0858
- Morais S, Rodrigues S, Amorim L, Peleteiro B, Lunet N. Tobacco smoking and intestinal metaplasia: systematic review and meta-analysis. Dig Liver Dis 2014; 46: 1031–7. doi: 10.1016/j.dld.2014.08.034
- Thrift AP, Jove AG, Liu Y, Tan MC, El-Serag HB. Associations of duration, intensity, and quantity of smoking with risk of gastric intestinal metaplasia. J Clin Gastroenterol 2022; 56: e71–e6. doi: 10.1097/MCG.0000000000001479
- Mao Y, Yang W, Qi Q, Yu F, Wang T, Zhang H, et al. Blood groups A and AB are associated with increased gastric cancer risk: evidence from a large genetic study and systematic review. BMC Cancer 2019; 19: 164. doi: 10.1186/s12885-019-5355-4
- Rizzato C, Kato I, Plummer M, Muñoz N, Stein A, Jan van Doorn L, et al. Risk of advanced gastric precancerous lesions in Helicobacter pylori infected subjects is influenced by ABO blood group and cagA status. Int J Cancer 2013; 133: 315–22. doi: 10.1002/ijc.28019
- Wang M, Lou E, Xue Z. The role of bile acid in intestinal metaplasia. Front Physiol 2023; 14: 1115250. doi: 10.3389/fphys.2023.1115250
- Yu J, Zheng J, Qi J, Yang K, Wu Y, Wang K, et al. Bile acids promote gastric intestinal metaplasia by upregulating CDX2 and MUC2 expression via the FXR/NF-κB signalling pathway. Int J Oncol 2019; 54: 879–92. doi: 10.3892/ijo.2019.4692
- Dias-Neto M, Pintalhao M, Ferreira M, Lunet N. Salt intake and risk of gastric intestinal metaplasia: systematic review and meta-analysis. Nutr Cancer 2010; 62: 133–47. doi: 10.1080/01635580903305391
- Song JH, Kim YS, Heo NJ, Lim JH, Yang SY, Chung GE, et al. high salt intake is associated with atrophic gastritis with intestinal metaplasia. Cancer Epidemiol Biomarkers Prev 2017; 26: 1133–8. doi: 10.1158/1055-9965.EPI-16-1024
- Wiseman M. The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Proc Nutr Soc 2008; 67: 253–6. doi: 10.1017/S002966510800712X
- Jencks DS, Adam JD, Borum ML, Koh JM, Stephen S, Doman DB. Overview of current concepts in gastric intestinal metaplasia and gastric cancer. Gastroenterol Hepatol (N Y) 2018; 14: 92–101. PMID: 29606921